New insights into the role of nuclear factor-κB, a ubiquitous transcription factor in the initiation of diseases

Clinical Chemistry

Volumn 45, Issue 1, 1999, Pages 7-17

  Chen, Fei ^a   Castranova, Vince ^a   Shi, Xianglin ^a   Demers, Laurence M ^b  

^a NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; APOPTOSIS; ARTHRITIS; ASTHMA; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CARCINOGENESIS; GLOMERULONEPHRITIS; HUMAN; INFLAMMATION; LUNG FIBROSIS; REVIEW; SEPTIC SHOCK;

BACTERIA (MICROORGANISMS);

EID: 0032900439     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.1.7     Document Type: Review

References (116)

1. 1. Baldwin AS Jr. The NF-κB, IκB proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-83.
2. 2. Finco TS, Baldwin AS. Mechanistic aspects of NF-κB regulation: the emerging role of phosphorylation and proteolysis. Immunity 1995;3:263-72.
3. 3. Barnes PJ, Karin M. Nuclear factor-κB - A pivotal transcription factor in chronic inflammatory diseases. New Engl J Med 1997; 366:1066-71.
4. 4. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986;46:705-16.
5. 5. Ahmad M, Marui N, Alexander RW, Medford RM. Cell type-specific transactivation of the VCAM-1 promoter through an NF-κB enhancer motif. J Biol Chem 1995;270:8976-83.
6. 6. Paxton LL, Li LJ, Secor V, Duff JL, Naik SM, Shibagaki N, Caughman SW. Flanking sequences for the human intercellular adhesion molecule-1 NF-κB response element are necessary for tumor necrosis factor α-induced gene expression. J Biol Chem 1997;272:15928-35.
7. 7. Aoudjit F, Brochu N, Belanger B, Stratowa C, Hiscott J, Audette M. Regulation of intercellular adhesion molecule-1 gene by tumor necrosis factor-α is mediated by the nuclear factor-κB heterodimers p65/p65 and p65/c-Rel in the absence of p50. Cell Growth Differ 1997;8:335-42.
8. 8. Vandermeeren M, Janssens S, Borgers M, Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun 1997;234:19-23.
9. 9. Lee DH, Tam SS, Wang E, Taylor GR, Plante RK, Lau CY. The NF-κB inhibitor, tepoxalin, suppresses surface expression of the cell adhesion molecules CD62E, CD11b/CD18 and CD106. Immunol Lett 1996;53:109-13.
10. 10. Ray P, Yang L, Zhang DH, Ghosh SK, Ray A. Selective up-regulation of cytokine-induced RANTES gene expression in lung epithelial cells by overexpression of IκBR. J Biol Chem 1997; 272:20191-7.
11. 11. Widmer U, Manogue KR, Cerami A, Sherry B. Genomic cloning and promoter analysis of macrophage inflammatory protein (MIP)-2, MIP-1 alpha, and MIP-1 beta, members of the chemokine superfamily of proinflammatory cytokines. J Immunol 1993; 150:4996-5012.
12. 12. Blackwell TS, Christman JW. The role of nuclear factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol 1997;17: 3-9.
13. 13. Gilmore TD. Clinically relevant finding. J Clin Investig 1997;100: 2935-6.
14. 14. Ohmori Y, Schreiber RD, Hamilton TA. Synergy between interferon-gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor κB. J Biol Chem 1997;272:14899-907.
15. 15. Bennett BL, Cruz R, Lacson RG, Manning AM. Interleukin-4 suppression of tumor necrosis factor alpha-stimulated E-selectin gene transcription is mediated by STAT6 antagonism of NF-κB. J Biol Chem 1997;272:10212-9.
16. 16. Handel ML. Transcription factors AP-1 and NF-κB: where steroids meet the gold standard of anti-rheumatic drugs. Inflamm Res 1997;46:282-6.
17. 17. Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci U S A 1997;94:2927-32.
18. 18. Bassuk AG, Anandappa RT, Leiden JM. Physical interactions between Ets and NF-κB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells. J Virol 1997;71:3563-73.
19. 19. Wolfe SA, Zhou P, Dotsch V, Chen L, You A, Ho SN, et al. Unusual Rel-like architecture in the DNA-binding domain of the transcription factor NFATc. Nature 1997;385:172-6.
20. 20. LeClair KP, Blanar MA, Sharp PA. The p50 subunit of NF-κB associates with the NF-IL6 transcription factor. Proc Natl Acad Sci U S A 1992;89:8145-9.
21. 21. Brown K, Franzoso G, Baldi L, Carlson L, Mills L, Lin YC, et al. The signal response of IκBα is regulated by transferable N-and C-terminal domains. Mol Cell Biol 1997;17:3021-7.
22. 22. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of IκBα proteolysis by site-specific, signal-induced phosphorylation. Science 1995;267:1485-8.
23. 23. Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S, Baeuerle PA. Phosphorylation of human IκBα on serines 32 and 36 controls IκBα proteolysis and NF-κB activation in response to diverse stimuli. EMBO J 1995;14:2876-83.
24. 24. Whiteside ST, Israel A. IκB proteins: structure, function and regulation. Semin Cancer Biol 1997;8:75-82.
25. 25. Chen Z, Hagler J, Palombella VJ, Melandri F, Scherer D, Ballard D, Maniatis T. Signal-induced site-specific phosphorylation targets IκBα to the ubiquitin-proteasome pathway. Genes Dev 1995;9:1586-97.
26. 26. Lindholm PF, Tamami M, Makowski J, Brady JN. Human T-cell lymphotropic virus type 1 Tax1 activation of NF-κB: involvement of the protein kinase C pathway. J Virol 1996;70:2525-32.
27. 27. Zhong H, SuYang H, Erdjument-Bromage H, Tempst P, Ghosh S. The transcriptional activity of NF-κB is regulated by the IκB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell 1997;89:413-24.
28. 28. Kumar A, Haque J, Lacoste J, Hiscott J, Williams BR. Double-stranded RNA-dependent protein kinase activates transcription factor NF-κB by phosphorylating IκB. Proc Natl Acad Sci U S A 1994;91:6288-92.
29. 29. Folgueira L, Algeciras A, MacMorran WS, Bren GD, Paya CV. The Ras-Raf pathway is activated in human immunodeficiency virus-infected monocytes and participates in the activation of NF-κB. J Virol 1996;70:2332-8.
30. 30. Janosch P, Schellerer M, Seitz T, Reim P, Eulitz M, Brielmeier M, et al. Characterization of IκB kinases. IκBα is not phosphorylated by Raf-1 or protein kinase C isozymes, but is a casein kinase II substrate. J Biol Chem 1996;271:13868-74.
31. 31. Ghosh S, Baltimore D. Activation in vitro of NF-κB by phosphorylation of its inhibitor IκB. Nature 1990;344:678-82.
32. 32. Ghoda L, Lin X, Greene WC. The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IκBα and stimulates its degradation in vitro. J Biol Chem 1997;272:21281-8.
33. 33. Chen ZJ, Parent L, Maniatis T. Site-specific phosphorylation of IκBα by a novel ubiquitination-dependent protein kinase activity. Cell 1996;84:853-62.
34. 34. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation. Cell 1997;91:243-52.
35. 35. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IκB kinase that activates the transcription factor NF-κB. Nature 1997;388:548-54.
36. 36. Regnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M. Identification and characterization of an IκB kinase. Cell 1997; 90:373-83.
37. 37. Woronicz JD, Gao X, Cao Z, Rothe M, Goeddel DV. IκB kinase-β: NF-κB activation and complex formation with IκB kinase-α and NIK. Science 1997;278:866-9.
38. 38. Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J, et al. IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation. Science 1997;278:860-6.
39. 39. Ling L, Cao Z, Goeddel DV. NF-κB-inducing kinase activates IKKα by phosphorylation of ser-176. Proc Natl Acad Sci U S A 1998;95:3792-7.
40. 40. Nakano H, Shindo M, Sakon S, Nishinaka S, Mihara M, Yagita H, Okumura K. Differential regulation of IκB kinase and by two upstream kinases, NF-κB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-I. Proc Natl Acad Sci U S A 1998;95:3537-42.
41. 41. Marianneau P, Cardona A, Edelman L, Deubel V, Despres P. Dengue virus replication in human hepatoma cells activates NF-κB which in turn induces apoptotic cell death. J Virol 1997: 71:3244-9.
42. 42. Baichwal VR, Baeuerle PA. Activate NF-κB or die? Curr Biol 1997;7:R94-6.
43. 43. Bessho R, Matsubara K, Kubota M, Kuwakado K, Hirota H, Wakazono Y, et al. Pyrrolidine dithiocarbamate, a potent inhibitor of nuclear factor κB (NF-κB) activation, prevents apoptosis in human promyelocytic leukemia HL-60 cells and thymocytes. Biochem Pharmacol 1994;48:1883-9.
44. 44. Kitajima I, Nakajima T, Imamura T, Takasaki I, Kawahara K, Okano T, et al. Induction of apoptosis in murine clonal osteoblasts expressed by human T-cell leukemia virus type I tax by NF-κB and TNF-α. J Bone Miner Res 1996;11:200-10.
45. 45. Kitajima I, Soejima Y, Takasaki I, Beppu H, Tokioka T, Maruyama I. Ceramide-induced nuclear translocation of NF-κB is a potential mediator of the apoptotic response to TNF-α in murine clonal osteoblasts. Bone 1996;19:263-70.
46. 46. Casano FJ, Rolando AM, Mudgett JS, Molineaux SM. The structure and complete nucleotide sequence of the murine gene encoding interleukin-1β converting enzyme (ICE). Genomics 1994;20:474-81.
47. 47. La Rosa FA, Pierce JW, Sonenshein GE. Differential regulation of the c-myc oncogene promoter by the NF-κB rel family of transcription factors. Mol Cell Biol 1994;14:1039-44.
48. 48. Trede NS, Tsytsykova AV, Chatila T, Goldfeld AE, Geha RS. Transcriptional activation of the human TNF-α promoter by superantigen in human monocytic cells: role of NF-κB. J Immunol 1995;155:902-8.
49. 49. Golstein P, Ojcius DM, Young JD. Cell death mechanisms and the immune system. Immunol Rev 1991;121:29-65.
50. 50. Mayo MW, Wang C, Cogswell PC, Rogers-Graham KS, Lowe SW, Der CJ, Baldwin AS Jr. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 1997;278:1812-5.
51. 51. Wang C, Mayo MW, Baldwin AS. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996; 274:784-7.
52. 52. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science 1996;274:787-9.
53. 53. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature 1995;376:167-70.
54. 54. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996;274:782-4.
55. 55. Wu M, Lee H, Bellas RE, Schauer SL, Arsura M, Katz D, et al. Inhibition of NF-κB/Rel induces apoptosis of murine B cells. EMBO J 1996;15:4682-90.
56. 56. Snapper CM, Zelazowski P, Rosas FR, Kehry MR, Tian M, Baltimore D, Sha WC. B cells from p50/NF-κB knockout mice have selective defects in proliferation, differentiation, germ-line CH transcription, and Ig class switching. J Immunol 1996;156: 183-91.
57. 57. Sha WC, Liou HC, Tuomanen El, Baltimore D. Targeted disruption of the p50 subunit of NF-κB leads to multifocal defects in immune responses. Cell 1995;80:321-30.
58. 58. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS Jr. A requirement for NF-κB activation in Bcr-Abl-mediated transformation. Genes Dev 1998;12:968-81.
59. 59. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappa B control. Proc Natl Acad Sci U S A 1997;94:10057-62.
60. 60. You M, Ku P-T, Hrdlickova R, Bose HR. ch-IAP1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein. Mol Cell Biol 1997; 17:7328-41.
61. 61. Wang C-Y, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and cIAP2 to suppress caspase-8 activation. Science 1998;281: 1680-3.
62. 62. Caamano JH, Rizzo CA, Durham SK, Barton DS, Raventos-Surarez C, Snapper CM, Bravo R. Nuclear factor κB2 (p100/52) is required for normal splenic microarchitecture and B cell-mediated immune response. J Exp Med 1998;187:185-96.
63. 63. Franzoso G, Carlson L, Poljak L, Shores EW, Epstein S, Leonardi A, et al. Mice deficient in NF-κB p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med 1998;187:147-59.
64. 64. Kontgen F, Grumont RJ, Strasser A, Metcalf D, Li R, Tarlinton D, Gerondakis S. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev 1995;9:1965-77.
65. 65. Burkly L, Hession C, Ogata L, Reilly C, Marconi LA, Olson D, et al. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature 1995;373:531-6.
66. 66. Weih F, Warr G, Yang H, Bravo R. Multifocal defects in immune responses in RelB-deficient mice. J Immunol 1997;158: 5211-8.
67. 67. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, et al. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev 1997;11:3482-96.
68. 68. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med 1997;3:1285-9.
69. 69. Ray A, Prefontaine KE, Ray P. Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor. J Biol Chem 1994;269:12940-6.
70. 70. Kabrun N, Enrietto PJ. The Rel family of proteins in oncogenesis and differentiation. Semin Cancer Biol 1994;5:103-12.
71. 71. Kanegae Y, Tavares AT, Belmonte JCI, Verma IM. Role of Rel/NF-κB transcription factors during the outgrowth of the vertebrate limb. Nature 1998;392:611-4.
72. 72. Bushdid PB, Brantley DM, Yull FE, Blaeuer GL, Hoffman LH, Niswander L, Kerr LD. Inhibition of NF-κB activity results in disruption of the apical ectodermal ridge and aberrant limb morphogenesis. Nature 1998;392:615-8.
73. 73. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE. Aberrant NF-κB/Rel expression and the pathogenesis of breast cancer. J Clin Investig 1997;100:2952-60.
74. 74. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997;17:3629-39.
75. 75. Mukhopadhyay T, Roth JA, Maxwell SA. Altered expression of the p50 subunit of the NF-κB transcription factor complex in non-small cell lung carcinoma. Oncogene 1995;11:999-1003.
76. 76. Gilmore TD, Koedood M, Piffat KA, White DW. Rel/NF-κB/IκB proteins and cancer. Oncogene 1996;13:1367-78.
77. 77. Bargou RC, Leng C, Krappmann D, Emmerich F, Mapara MY, Bommert K, et al. High-level nuclear NF-κB and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996;87:4340-7.
78. 78. Miwa M, Kushida S, Maeda N, Fang J, Kawamura T, Kameyama T, Uchida K. Pathogenesis and prevention of HTLV-1-associated diseases. Leukemia 1997;11(Suppl 3):65-6.
79. 79. Berger C, Brousset P, McQuain C, Knecht H. Deletion variants within the NF-κB activation domain of the LMP1 oncogene in acquired immunodeficiency syndrome-related large cell lymphomas, in prelymphomas and atypical lymphoproliferations. Leukemia Lymphoma 1997;26:239-50.
80. 80. Blumberg BS. The current state of the prevention of HBV infection, the carrier state and hepatocellular carcinoma. Res Virol 1997;148:91-4.
81. 81. Nasti G, Vaccher E, Errante D, Tirelli U. Malignant tumors and AIDS. Biomed Pharmacother 1997;51:243-51.
82. 82. Liptay S, Seriu T, Bartram CR, Schmid RM. Germline configuration of nfkb2, c-rel and bcl3 in childhood acute lymphoblastic leukemia (ALL). Leukemia 1997;11:1364-6.
83. 83. Houldsworth J, Mathew S, Rao PH, Dyomina K, Louie DC, Parsa N, et al. REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood 1996;87:25-9.
84. 84. Michaux L, Dierlamm J, Wlodarska I, Bours V, Van den Berghe H, Hagemeijer A. t(14;19)/BCL3 rearrangements in lymphoproliferative disorders: a review of 23 cases. Cancer Genet Cytogenet 1997;94:36-43.
85. 85. Hiscott J, Beauparlant P, Crepieux P, DeLuca C, Kwon H, Lin R, Petropoulos L. Cellular and viral protein interactions regulating IκBα activity during human retrovirus infection. J Leuk Biol 1997;62:82-92.
86. 86. Sandberg M, Hammerschmidt W, Sugden B. Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3. J Virol 1997;71:4649-56.
87. 87. Lucito R, Schneider RJ. Hepatitis B virus X protein activates transcription factor NF-κB without a requirement for protein kinase C. J Virol 1992;66:983-91.
88. 88. Mhashilkar AM, Biswas DK, LaVecchio J, Pardee AB, Marasco WA. Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-κB antagonists. J Virol 1997;71:6486-94.
89. 89. Kitajima I, Shinohara T, Bilakovics J, Brown DA, Xu X, Nerenberg M. Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-κB. Science 1992;258: 1792-5.
90. 90. Carrasco D, Rizzo CA, Derfman K, Bravo R. The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice. EMBO J 1996;15:3640-50.
91. 91. Carrasco D, Perez P, Lewin A, Bravo R. IκBα overexpression delays tumor formation in v-rel transgenic mice. J Exp Med 1997;186:279-88.
92. 92. Mosialos G, Gilmore TD. v-Rel, c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence. Oncogene 1993;8:721-30.
93. 93. Sachdev S, Diehl JA, McKinsey TA, Hans A, Hannink M. A threshold nuclear level of the v-Rel oncoprotein is required for transformation of avian lymphocytes. Oncogene 1997;14:2585-94.
94. 94. Schulze-Osthoff K, Los M, Baeuerle PA. Redox signalling by transcription factors NF-κB and AP-1 in lymphocytes. Biochem Pharmacol 1995;50:735-41.
95. 95. Beauparlant P, Hiscott J. Biological and biochemical inhibitors of the NF-κB/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev 1996;7:175-90.
96. 96. Chen F, Lu Y, Kuhn DC, Maki M, Shi X, Sun SC, Demers LM. Calpain contributes to silica-induced IκBα degradation and nuclear factor-κB activation. Arch Biochem Biophys 1997;342: 383-8.
97. 97. Unlap MT, Jope RS. Dexamethasone attenuates NF-κB DNA binding activity without inducing IκB levels in rat brain in vivo. Mol Brain Res 1997;45:83-9.
98. 98. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of IκB alpha in mediation of immunosuppression by glucocorticoids. Science 1995;270:283-6.
99. 99. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 1995;270:286-90.
100. 100. Kukovetz WR, Holzmann S, Schmidt K. Cellular mechanisms of action of therapeutic nitric oxide donors. Eur Heart J 1991; 12(Suppl E):16-24.
101. 101. Chen F, Sun SC, Kuhn DC, Gaydos LJ, Demers LM. Essential role of NF-κB activation in silica-induced inflammatory mediator production in macrophages. Biochem Biophys Res Commun 1995; 214:985-92.
102. 102. Chen F, Kuhn DC, Sun SC, Gaydos LJ, Demers LM. Dependence and reversal of nitric oxide production on NF-κB in silica and lipopolysaccharide-induced macrophages. Biochem Biophys Res Commun 1995;214:839-46.
103. 103. Matthews JR, Botting CH, Panico M, Morris HR, Hay RT. Inhibition of NF-κB DNA binding by nitric oxide. Nucleic Acids Res 1996;24:2236-42.
104. 104. Spiecker M, Peng HB, Liao JK. Inhibition of endothelial vascular cell adhesion molecule-1 expression by nitric oxide involves the induction and nuclear translocation of IκBα. J Biol Chem 1997; 272:30969-74.
105. 105. Shin WS, Hong YH, Peng HB, De Caterina R, Libby P, Liao JK. Nitric oxide attenuates vascular smooth muscle cell activation by interferon-gamma. The role of constitutive NF-kappa B activity. J Biol Chem 1996;271:11317-24.
106. 106. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Investig 1995;96:60-8.
107. 107. Peng HB, Libby P, Liao JK. Induction and stabilization of IκBα by nitric oxide mediates inhibition of NF-κB. J Biol Chem 1995;270: 14214-9.
108. 108. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat Med 1996;2:998-1004.
109. 109. Crofford LJ, Tan B, McCarthy CJ, Hla T. Involvement of nuclear factor κB in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes. Arthritis Rheumatism 1997;40:226-36.
110. 110. Roshak AK, Jackson JR, McGough K, Chabot-Fletcher M, Mochan E, Marshall LA. Manipulation of distinct NF-κB proteins alters interleukin-1β-induced human rheumatoid synovial fibroblast prostaglandin E2 formation. J Biol Chem 1996;271:31496-501.
111. 111. Bielinska A, Shivdasani RA, Zhang LQ, Nabel GJ. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science 1990;250:997-1000.
112. 112. Khaled AR, Butfiloski EJ, Sobel ES, Schiffenbauer J. Use of phosphorothioate-modified oligodeoxynucleotides to inhibit NF-κB expression and lymphocyte function. Clin Immunol Immunopathol 1998;86:170-9.
113. 113. Yanagihara Y, Basaki Y, Kajiwara K, Ikizawa K. A thiol antioxidant regulates IgE isotype switching by inhibiting activation of nuclear factor-κB. J Allergy Clin Immunol 1997;100:S33-8.
114. 114. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, et al. In vivo transfection of cis element "decoy" against nuclear factor-κB binding site prevents myocardial infarction. Nat Med 1997;3:894-9.
115. 115. Bustamante JO, Oberleithner H, Hanover JA, Liepins A. Patch clamp detection of transcription factor translocation along the nuclear pore complex channel. J Membrane Biol 1995;146: 253-61.
116. 116. Foulds S. Novel flow cytometric method for quantifying nuclear binding of the transcription factor nuclear factor κB in unseparated human monocytes and polymorphonuclear cells. Cytometry 1997;29:182-6.